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Abstract
Introduction The dynamics of breast cancer recurrence and
death, indicating a bimodal hazard rate pattern, has been
confirmed in various databases. A few explanations have been
suggested to help interpret this finding, assuming that each
peak is generated by clustering of similar recurrences and
different peaks result from distinct categories of recurrence.
Methods The recurrence dynamics was analysed in a series of
1526 patients undergoing conservative surgery at the National
Cancer Institute of Milan, Italy, for whom the site of first
recurrence was recorded. The study was focused on the first
clinically relevant event occurring during the follow up (ie, local
recurrence, distant metastasis, contralateral breast cancer,
second primary tumour), the dynamics of which was studied by
estimating the specific hazard rate.
Results The hazard rate for any recurrence (including both local
and distant disease relapses) displayed a bimodal pattern with
a first surge peaking at about 24 months and a second peak at
almost 60 months. The same pattern was observed when the
whole recurrence risk was split into the risk of local recurrence
and the risk of distant metastasis. However, the hazard rate
curves for both contralateral breast tumours and second primary
tumours revealed a uniform course at an almost constant level.
When patients with distant metastases were grouped by site of
recurrence (soft tissue, bone, lung or liver or central nervous
system), the corresponding hazard rate curves displayed the
typical bimodal pattern with a first peak at about 24 months and
a later peak at about 60 months.
Conclusions The bimodal dynamics for early stage breast
cancer recurrence is again confirmed, providing support to the
proposed tumour-dormancy-based model. The recurrence
dynamics does not depend on the site of metastasis indicating
that the timing of recurrences is generated by factors influencing
the metastatic development regardless of the seeded organ.
This finding supports the view that the disease course after
surgical removal of the primary tumour follows a common
pathway with well-defined steps and that the recurrence risk
pattern results from inherent features of the metastasis
development process, which are apparently attributable to
tumour cells.
Introduction
The dynamics of disease recurrence has been investigated
previously in a series of 1173 patients undergoing mastec-
tomy as single initial treatment for early stage breast cancer at
the National Cancer Institute of Milan, Italy [1-3]. The hazard
rate for recurrence indicated a bimodal relapse pattern with an
early, rather sharp, dominant peak at about two years and a
second broader peak at about five years with a decay that
extended to at least 15 years. The finding has been confirmed
in other databases for both recurrence [4-8] and mortality [9-
13], and was even evident when patients received adjuvant
chemotherapy [8]. It was not predicted by any prevailing the-
ory of breast cancer evolution that was considered to have
originated from unrestrained continuous cellular growth. The
multipeak hazard rate for recurrence implied heterogeneity of
treatment failure.
AIC: Akaike Information Criterion; df: degrees of freedom; ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; N-: axillary node 
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To explain the bimodal pattern, a simple metastasis develop-
ment model was proposed [14,15] consisting of three distinct
phases: a single malignant cell, an avascular lesion and a vas-
cularised growth. Tumour dormancy was assumed to be pos-
sible at the single cell level and also at the point where, for
further growth, angiogenesis is necessary [14]. The model
was able to simulate [15] the second peak as a steady sto-
chastic progression from one phase to the next. In order to
simulate the first peak, however, it was postulated that for
some subsets of patients, transitions from one state to the next
were stimulated at or about the time of surgery. The conclu-
sions were that the dominant mode of relapse in early stage
breast cancer was the result of events terminating dormancy
phases at the time of surgery.
Other explanations for the bimodal hazard rate pattern have
also been suggested. Attempts to evaluate the role of local fail-
ure in distant failure and survival led to the hypothesis that the
second recurrence surge originated by distant metastases
started by a prior local failure, involving delicate issues in the
formalisation and interpretation of the analyses [5]. Research-
ers analysing breast cancer mortality have suggested that
bimodal patterns could result from the heterogeneous "malig-
nant potential" of breast cancer [12]. According to this latter
hypothesis, the two mortality peaks are attributable to different
types of failure caused either by early and late tumour relapse
or by local tumour recurrence and distant metastasis. Underly-
ing these explanations is the concept that the hazard rate pat-
tern should be explained by a juxtaposing of populations with
different, yet uniform, disease development. They suggest that
each peak is generated by clustering similar recurrences while
different peaks result from distinct categories of recurrence.
Instead of that explanation, the proposed tumour-dormancy-
based model is essentially saltatory and suggests that the
occurrence of different peaks is generated by the intrinsic gen-
eral process of the metastatic development, although the
underlying mechanism still remains unclear.
In the present study we analysed the recurrence dynamics in
a further series of patients undergoing conservative surgery at
the National Cancer Institute of Milan, for whom the site of first
recurrence was recorded. The study provides evidence that
different categories of metastases display the same bimodal
hazard rate pattern. This finding supports the view that the dis-
ease course after surgical removal of a primary tumour follows
a common pathway with well-defined steps and that the recur-
rence risk pattern results from inherent features of the metas-
tasis development process, which are apparently attributable
to tumour cells.
Materials and methods
Patients
The preliminary results of the Milan trial comparing quadran-
tectomy plus radiotherapy (QUART) to mastectomy were
obtained in 1980, and since then routine practice at the
National Cancer Institute of Milan has been conservative treat-
ment of early breast cancer, following informed consent of the
patient. Patients undergoing the clinical treatment with
QUART, who were not included in a randomised clinical trial
and who met the same criteria implemented for trial cases
[16], were included in the study (out-trial patients). Briefly, out-
trial patients with unilateral primary breast cancer up to 3.5 cm
in diameter, clinically uninvolved axillary lymph nodes and no
other evidence of tumour spread received QUART. Quadran-
tectomy was performed by removing the primary tumour and a
2 to 3 cm margin of normal mammary tissue. Axillary lymph
nodes were completely excised. Radiotherapy to the ipsilateral
breast (50 Gy with high energy plus 10 Gy as a boost with
orthovoltage) was started within one month of surgery.
Women with histologically positive axillary nodes were allo-
cated to receive systemic adjuvant treatment.
Patients were followed up quarterly for the first five years and
then twice a year. Chest x-ray was performed every six months
for the first five years and then every year. Bone and liver scans
and mammographies were performed every year. If any symp-
toms or signs suggestive of a potential recurrence were
detected or reported by the patients, focused investigations
were carried out. If recurrence was documented, a complete
restaging was obtained. All baseline data, treatment features
and relevant clinical events were collected in standard format
and stored in a clinical database. Data about a few currently
assessed biological markers (ie, oestrogen receptor (ER), pro-
gesterone receptor (PR) and human epidermal growth recep-
tor 2 (HER2)) were not systematically recorded and were not
considered in the analysis. Also, information about familial risk
factors was not available.
This study focused on the first clinically relevant event occur-
ring during the follow-up period, that is local recurrence, dis-
tant metastasis, contralateral breast cancer and second
primary tumour. Local recurrence was defined as any new
breast cancer appearance in the breast already operated on
only. Distant metastasis was defined as any breast cancer
manifestation(s) in areas other than that of local recurrence
with the exception of the contralateral breast, where it was
defined as contralateral breast cancer. Primary malignant
tumours in other organs were defined as second primaries.
Distant metastases were categorised as bone, viscera and
soft tissue recurrences according to previously defined criteria
[17]. In the case of synchronous visceral and non-visceral
localisations the recurrence was recorded as multiple visceral.
Soft tissue metastases also included the supra-clavicular
lymph node recurrences.
Statistical analysis
The recurrence dynamics was studied using the life-table
method to estimate the hazard rate for recurrence, that is, the
conditional probability of manifesting recurrence in a time
interval, given that the patient is clinically free of anyAvailable online http://breast-cancer-research.com/content/10/5/R83
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recurrence at the beginning of the interval. We applied a dis-
cretization of the time axis in a variety of units. Each calculated
value represents the measure of the hazard rate for recurrence
within the considered time unit. Although the hazard rate esti-
mates display some instability due to random variation, a Ker-
nel-like smoothing procedure [18] was adopted to aid the
interpretation of the underlying pattern, and the smoothed
curves were graphically represented. Different time intervals
were utilised in a preliminary smoothing analysis that showed
three-month intervals were a good compromise between
smoothing data and displaying the underlying structure. There-
fore, all hazard rate levels were measured as 'events/patients
at risk per three-month interval'.
In addition to the kernel smoothing approach with discrete
hazards, a formal flexible regression modelling strategy was
adopted as proposed by Boracchi and colleagues [19].
Because of the exploratory nature of the present study, B-
spline transformations over time were used [20] instead of the
truncated power spline notation approach, to allow for
smoothed multimodal hazard patterns over the entire follow-up
length. To account for different behaviours according to the
specific event of interest, the statistical models jointly analysed
all the events, allowing for interactions between the time bases
and event indicators, considering B-spline bases with degrees
of freedom (df) ranging from 4 to 10. Therefore, the evidence
of different patterns according to different events was infor-
mally assessed by selecting the best models according to the
Akaike Information Criterion (AIC) (Tables 1 and 2).
Results
A total of 1526 patients who received QUART during the 10
years between 1974 and 1984 and were not included in any
other clinical trial are incorporated in this analysis. The main
patient characteristics are summarised in Table 3. Patients
were generally young (41% less than 45 years) premenopau-
sal (60%) women with small tumours (90% T1), who under-
went a uniform treatment with standard QUART delivered by
the same clinical team. Adjuvant cyclophosphamide, meth-
otrexate plus fluorouracil therapy was administered to most
(70%) node-positive cases.
The first event was local recurrence in 119 patients and dis-
tant metastasis in 280 patients, and in 73 cases a contralateral
breast cancer was first recorded and further 39 patients devel-
oped a second primary as first event.
The hazard rate for any recurrence (including both local and
distant disease relapses) displayed a bimodal pattern with a
first surge peaking at about 24 months (estimated risk value =
0.016) and a second peak at almost 60 months (estimated risk
value = 0.009) (Figure 1a). The same pattern was observed
when the whole recurrence risk was split into its components:
the risk of local recurrence and the risk of distant metastasis
(Figure 1b). The hazard rate curves for both contralateral
breast tumours and second primary tumours did not show
major peaks but revealed an almost uniform course at a quite
constant level of about 0.002 for contralateral breast tumours
and about 0.001 for second primary tumours (Figures 1c and
1d).
The pattern of the hazard function for the analysed events was
confirmed by the flexible regression spline models. The
selected model, according to the AIC, had 5 df on time includ-
ing the interaction with the event type indicator, thus support-
ing the evidence of a different hazard shape behaviour
according to the different events. The estimated cause spe-
cific hazard curves from the selected interaction models are
reported in Figure 2. The bimodal behaviour of distant metas-
tasis is also evident from such an analysis, as well as the uni-
form tendency of contralateral breast cancers and second
primaries. With regard to local recurrences, the analysis did
not yield any evidence of a second peak. However, this fact
does not imply the absence of such a pattern because of the
parametric nature of the regression modelling approach,
focused on major effects rather than local behaviours accord-
ing to the available sample information.
Among patients with a first recurrence at a distant site, 98
women showed bone metastasis only, 45 cases had clinically
evident foci in soft tissue(s) and in a further 135 patients the
disease reappeared in visceral sites, either as single organ
involvement or as multiple recurrence in association with other
visceral, soft tissue or bone localisations. According to the
study aims, the assessment of recurrence dynamics should
have been focused on each single site. However, because of
the limited number of events to a single visceral site, recur-
rences to lung, liver or CNS were merged to obtain a more
suitable collection of 60 cases, representative of the visceral
recurrence. Therefore, three subsets of distantly recurring
p a t i e n t s  ( t o  s o f t  t i s s u e ,  b o n e ,  l u n g  o r  l i v e r  o r  C N S )  w e r e
Table 1
Hazard rate model AIC values for the analysis of distant 
recurrences, local recurrences, contralateral breast cancer and 
other primary tumours
4 234.9 212.2
5 224.8 208.4
6 225.2 221.2
7 227.4 218.8
8 228.1 224.5
9 230.2 231.2
10 230.9 235.6
The table reports Akaike Information Criterion (AIC) values according 
to the different models. The minimum value is reported in bold with 
the corresponding degrees of freedom indicating the informally 
selected model.Breast Cancer Research    Vol 10 No 5    Demicheli et al.
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analysed. The selected model, according to the AIC, had 6 df
on time without including the interaction with the recurrence
site indicator and did not support any evidence of a different
hazard shape behaviour according to the different events. The
corresponding hazard rate curves displayed the typical bimo-
dal pattern (Figure 3). In particular, the position of the first peak
on the time axis is at about 24 months while the later peak
emerges at about 60 months for all recurrence sites.
Discussion
The results of this study confirm previous findings and include
further details of the metastatic process, providing additional
support to the proposed tumour-dormancy-based model. In
particular, the results show that peaks are not determined by
similar clustering of given categories of metastasis and sug-
gest that the different timing of recurrences is generated by
factors influencing the metastatic development regardless of
the seeded organ. Regrettably, analysed data were lacking
information about some important biomarkers such as ER, PR
and HER2 that could have provided more information about
mechanisms underlying the bimodal kinetics.
The bimodal recurrence risk pattern is once again emerging
from the clinical data of this new series of patients as a current
feature of the recurrence dynamics. The peak position on the
time axis is unchanged in comparison to the findings from the
previously analysed series of patients [3]. In the present anal-
ysis we found lower peaks estimating the three-month recur-
rence risk level (0.016 versus 0.033 for the first peak and
0.009 versus 0.014 for the second peak) than in the previous
study. This finding is well explained by the different character-
istics of the two studied populations. Indeed, this analysis
included fewer patients with a poor prognosis (10% tumour
size of 2 cm or more, 37% N+, no adjuvant chemotherapy for
30% N+ patients) than the previous one (60% tumour size 2
cm or more, 49% N+, no adjuvant chemotherapy for any N+
patient) [3], accounting for the observed differences. When
comparing the present series to the T1 subset of the previous
series, even peak height differences almost do not exist (data
not shown).
As previously observed [2], both contralateral breast cancers
and second primaries display a quite constant hazard rate pat-
tern, confirming that the occurrence of contralateral breast
cancer should be considered a 'memory-less' stochastic event
unrelated to the primary tumour [21,22] or tumours developing
in other organs. This concept is further strengthened by the
estimated annual risk level, which is greater for contralateral
breast tumours than for other second primaries, as it may be
expected in these patients who should be considered at
higher-than-average risk for breast cancer (Figures 1c, d and
2).
The hazard rate for local recurrence presents a bimodal curve
analogous to the curve of distant metastasis. The two curves
cross at about eight years, when the risk of local recurrence
ceases to decrease, while the hazard rate for distant metasta-
sis goes on to regularly drop (Figures 1b and 1c). In previously
analysed patients who underwent mastectomy [2], the risk of
local recurrence showed a definite decreasing pattern after
the second peak and promptly reached an almost null level. It
should be taken into account, however, that women undergo-
ing QUART maintain a significant portion of their mammary
gland while in patients having mastectomy the breast area is
totally cleared of breast tissue. Therefore, patients who
undergo QUART may develop a further breast primary (some-
times from ductal carcinoma in situ) in the residual paren-
chyma while patients who undergo a mastectomy do not.
According to this hypothesis, which was devised since the
publication of the early reports on breast cancer conservative
surgery [16,23] and repeatedly discussed in further reports
[24-27], the hazard rate for local recurrence is the superimpo-
sition of the curve resulting from the true local recurrences and
the straight line paralleling the time axis resulting from the
memory-less stochastic appearance of a further ipsilateral
breast cancer. The resulting hazard rate curve, therefore, is
expected to show a right-sided tail at an almost constant level,
Table 2
Hazard rate model AIC values for the analysis of distant recurrences in different sites
Spline degrees of freedom AIC (models without interaction) AIC (Models with interaction)
5 110.1 117.9
61 0 6 . 4 112.3
7 106.8 115.4
8 106.9 117.5
9 111.5 120.5
10 113.0 124.1
The table reports Akaike Information Criterion (AIC) values according to the different models. The minimum value is reported in bold with the 
corresponding degrees of freedom indicating the informally selected model.Available online http://breast-cancer-research.com/content/10/5/R83
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as in fact occurs (Figures 1b and 2). Distinguishing between
true recurrence and second ipsilateral primary is clinically rel-
evant and has been widely pursued [26-29], although without
firm results until now.
The analysis of the hazard rate for distant metastases to differ-
ent organs consistently suggests that the recurrence dynam-
ics does not depend on the site of metastasis. This occurrence
supports the concept that the recurrence risk pattern results
from inherent features of the metastasis development process,
which are apparently attributable to tumour cells, although the
local micro-environmental host conditions should be permis-
sive for further metastasis growth. This result has been partially
anticipated [2] by the bimodal risk pattern for local recurrence,
which may be viewed as a type of soft tissue metastasis in
patients undergoing mastectomy and lacking residual breast
parenchyma. However, no firm conclusion had been reached
given that local recurrences may develop even from tumour
cell deposits subsequent to incomplete surgical clearing,
therefore not being representative of the metastatic process.
The results presented here remove any doubt about this issue
and suggest that some traits of the metastasis development
process are similar in all seeded organs.
The present findings provide new elements for a reassessment
of previously proposed explanations of the bimodal hazard rate
pattern, all assuming a uniform development of the micro-
scopic disease. The explanation suggested by Fortin and col-
leagues [5] fails to elucidate both the present and previous [2]
findings: their opinion that the "second peak can be explained
only by a second event, namely local failure" are not valid for
findings obtained from our analyses that are focused on first
events. Beyond this methodological drawback, however, we
wish to emphasise that the proposed explanation implies that
an observed peak should be related to patients dynamically
clustered (eg, patients displaying local recurrence). A similar
conceptual criticism can be addressed to the work by Yakov-
lev and colleagues [12], who found a two-component struc-
ture of the hazard function in breast cancer survival and
suggested possible explanations based on the heterogeneity
of "malignant potential" remaining in treated tumours. The sug-
gested explanations, that patients with different types of failure
(more vs less rapidly evolving disease) or different site of fail-
ure (local vs distant) produce different peaks, assume that
each peak is generated by the clustering of cases with similar
features, although different peaks result from distinct catego-
ries of patients.
The results of the present study argue against these views and
support the concept that different peaks are related to the
intrinsic general pathway of the metastasis development, not
to distinct categories of recurrence. Indeed, our results
provide evidence that the recurrence dynamics in different
metastatic sites is similar to the recurrence dynamics found in
different patient subsets [2,3,8], suggesting that the disease
course after surgical removal of a primary tumour apparently
follows a basic common pathway with well-defined steps. The
proposed tumour-dormancy-based model recognises such
steps as metastatic dormant states at the single cell level and
avascular micrometastasis level [3,8,14], and relates the haz-
ard rate pattern for recurrence to the non-linear disease devel-
opment. Within the common rhythm of the recurrence
dynamics, the risk levels at a certain time are influenced by
tumour and host traits [3,14], suggesting that the pace of the
common pathway is governed by a specific mixture of factors.
The delayed appearance of metastases has driven several
explanations, a few of which supported by the results of
sophisticated molecular techniques such as whole-genome
analysis or gene expression profiling [30,31]. Ductal carci-
noma in situ lesions and even disseminated tumour cells seed-
ing distant sites would need extra time to cumulate additional
Table 3
Main patient characteristics
Total number 1526
Age (years)
≤ 45 625
46 to 55 468
56 to 65 283
> 65 150
Menopausal status
Pre 922
Post 594
Unknown 10
Tumour size
≤ 1 cm 587
1.1 to 2 cm 779
2.1 to 3 cm 143
> 3 cm 17
Nodal status
N- 964
1 to 3 N+ 416
>3 N+ 146
Adjuvant therapy for N+ patients
None 45
CMF 394
Tamoxifen 30
Other 3
Unknown 90
N- = axillary node negative; N+ = axillary node positive; CMF = 
cyclophosphamide, methotrexate plus fluorouracil therapy.Breast Cancer Research    Vol 10 No 5    Demicheli et al.
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genetic progression and develop into invasive cancers. At
present, however, it remains unclear how such mechanisms
may account for the observed recurrence dynamics with its
cadences. Future studies are needed to find connections
between these explanations and the tumour dormancy hypoth-
esis, which at present seems to fit the clinical findings
adequately.
Conclusion
In the present study we analysed the recurrence dynamics in
a series of patients undergoing conservative surgery at the
National Cancer Institute of Milan. The recurrence dynamics
was studied with the life-table method to estimate the hazard
rate for recurrence, that is, the conditional probability of mani-
festing recurrence in a time interval, given that the patient is
clinically free of any recurrence at the beginning of the interval.
Moreover, the analysis was focused on the first clinically rele-
vant event occurring during the follow up, that is, local recur-
rence, distant metastasis, contralateral breast cancer and
second primary.
The bimodal recurrence risk pattern emerged from the clinical
data of this new series of patients as a current feature of the
recurrence dynamics. The peak position on the time axis was
unchanged in comparison to the findings from the previously
analysed series of patients, with an early peak at about two
years and a second broader peak at about five years with a
decay afterwards.
Three subsets of distantly recurring patients (to soft tissue,
bone and viscera) were analysed and the analysis did not sup-
port any evidence of a different hazard shape behaviour
according to the different events. The corresponding hazard
rate curves displayed the typical bimodal pattern and, in par-
ticular, the position of the first peak on the time axis was at
about 24 months, while the later peak emerged at about 60
months for all recurrence sites.
The study provides evidence that different categories of
metastases display the same bimodal hazard rate pattern.
Therefore, the concept that different peaks result from distinct
categories of patients such as patients with different types of
failure (eg, more vs less rapidly evolving disease) or different
Figure 1
Hazard rate estimates for selected events in 1526 patients undergoing conservative surgery Hazard rate estimates for selected events in 1526 patients undergoing conservative surgery. Each point represents the measure of the hazard 
rate of the given event within a three-month interval. The smoothed curve was obtained by a Kernel-like smoothing procedure. (a) Hazard rate for any 
recurrence (including both local and distant disease relapses). (b) The hazard rate for recurrence is split into its components: local recurrence (red 
line) and distant metastasis (blue line). (c) Hazard rate for contralateral breast cancer. (d) Hazard rate for second primary cancer.Available online http://breast-cancer-research.com/content/10/5/R83
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site of failure (eg, local vs distant or viscera vs bone) fails to be
supported. Rather, the study maintains the view that breast
cancer course after surgical removal of a primary tumour fol-
lows a common pathway with well-defined steps and that the
recurrence risk pattern results from inherent features of the
metastasis development process, which are apparently attrib-
utable to tumour cells, although the local host micro-environ-
mental conditions should be permissive for further metastasis
growth.
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Figure 2
Hazard rate for selected events in 1526 patients undergoing conservative surgery Hazard rate for selected events in 1526 patients undergoing conservative surgery. The same events as in Figure 1 were analysed by a formal 
flexible regression modelling strategy considering B-spline bases with degrees of freedom ranging from 4 to 10 and selecting the best models 
according to the Akaike Information Criterion. Vertical lines represent point-wise confidence interval for the model estimated hazards, according to 
standard asymptotic theory.
Figure 3
Hazard rate for distant metastasis in different sites Hazard rate for distant metastasis in different sites. Distant metastases were categorised as bone, viscera and soft tissue recurrences. Soft tis-
sue metastases also included the supra-clavicular lymph node recurrences. Because of the limited number of events to a single visceral site, recur-
rences to lung, liver or CNS were merged to obtain a more suitable collection of cases, representative of the visceral recurrence. Vertical lines 
represent point-wise confidence intervals for the model estimated hazards, according to standard asymptotic theory.Breast Cancer Research    Vol 10 No 5    Demicheli et al.
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